Results 61 to 70 of about 20,923 (159)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes

, 2016
Kashif M Munir,1 Stephen N Davis2 1Division of Endocrinology, Diabetes, and Nutrition, Center for Diabetes and Endocrinology, 2Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: With rates of obesity and ...
Munir KM, Davis SN
core  

Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet

BMJ Open Diabetes Research & Care, 2019
Objective We reported previously that empagliflozin—a sodium-glucose cotransporter (SGLT) 2 inhibitor—exhibited preventive effects against obesity. However, it was difficult to extrapolate these results to human subjects. Here, we performed a therapeutic
Tsuguhito Ota, Shuichi Kaneko, Liang Xu, Naoto Nagata, Guanliang Chen, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Yuriko Sakai   +8 more
doaj   +1 more source

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?

, 2017
Francisco Javier Ampudia‑Blasco,1 Irene Romera,2 Bernat Ariño,3 Ramón Gomis4 1Endocrinology and Nutrition Department, Clinic University Hospital Valencia, Valencia, Spain; 2Eli Lilly and Company España, Madrid, Spain; 3Boehringer ...
Gomis R, Romera I, Ariño B, Ampudia-Blasco FJ   +3 more
core  

Szilárd gyógyszerhatóanyag maradék oldószertartalmának meghatározása Headspace gázkromatográfiás technikával

, 2015
Szakdolgozatomban összefoglaltam az Empagliflozin maradék oldószertartalmának meghatározását.
Orovecz, Viktória
core  

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Biochemistry and Biophysics Reports, 2019
Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice ...
Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, Takeshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Ryoko Motonaga, Takashi Fukuda, Makito Tanabe, Toshihiko Yanase   +10 more
doaj   +1 more source

Empagliflozin in the treatment of type 2 diabetes: evidence to date

, 2015
Jay H Shubrook,1 Babak Baradar Bokaie,2 Sarah E Adkins31Primary Care Department, Clinical Research and Diabetes Services, Touro University College of Osteopathic Medicine, Vallejo, CA, USA; 2The Diabetes Institute at Ohio University, Ohio University ...
Shubrook JH, Baradar Bokaie B, Adkins SE
core  

The role of empagliflozin in the management of type 2 diabetes by patient profile

, 2015
Maka S Hedrington, Stephen N Davis Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA Abstract: Current recommendations for the management of type 2 diabetes mellitus (T2DM) include patient-centered approach, ie ...
Hedrington MS, Davis SN
core  

Dapagliflozin, Empagliflozin ve Eksenatid Kullanan Tip 2 Diyabetli Hastalarda Kardiyovasküler Olay Oranlarının Retrospektif Olarak Değerlendirilmesi

Uludağ Üniversitesi Tıp Fakültesi Dergisi
Tip 2 diyabet hastalarında kardiyovasküler hastalıklar diyabeti olmayanlara göre daha yüksektir. SGLT-2 inhibitörlerinin (empagliflozin, dapagliflozin vb.) ve GLP-1 analoglarının (exenatid vb.) kardiyak etkilerine ilişkin olumlu sonuçlar veren geniş ...
Bahriye Gültaş, Soner Cander, Özen Öz Gül   +2 more
doaj   +1 more source

Efficacy and Safety of Adding Empagliflozin to Liraglutide on Renal Function in Patients with Advanced-Stage Type 2 Diabetic Kidney Disease: A Randomized Controlled Trial [PDF]

Kae Sunagawa,1,2 Keiji Hirai,3 Sumito Sunagawa,1,2 Norifumi Kamiya,1 Isao Komesu,1 Yusako Sunagawa,1 Hiroshi Sunagawa,1 Ken Nakachi,4 Aizan Hirai,5 Susumu Ookawara,3 Yoshiyuki Morishita3 1Sunagawa Medical Clinic, Okinawa, Japan; 2Division of ...
Sunagawa K, Sunagawa H, Hirai K, Komesu I, Nakachi K, Sunagawa Y, Morishita Y, Sunagawa S, Hirai A, Kamiya N, Ookawara S   +10 more
core  

Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia

Frontiers in Pharmacology
Background and aimsRecent studies suggest that empagliflozin reduces total and cardiovascular mortality in both diabetic and nondiabetic subjects. Although the exact mechanism is unclear, it is understood to positively affect myocardial energetics ...
Denisa Miklankova, Denisa Miklankova, Irena Markova, Martina Hüttl, Hana Malinska   +4 more
doaj   +1 more source